Recent progress in immunoprophylaxis of severe acute respiratory syndrome coronavirus 2 in children younger than 5 years
10.3760/cma.j.cn101070-20220705-00824
- VernacularTitle:5岁以下儿童新型冠状病毒感染的免疫预防最新进展
- Author:
Fengxia XUE
1
;
Kunling SHEN
Author Information
1. 国家儿童医学中心，国家呼吸系统疾病临床医学研究中心，首都医科大学附属北京儿童医院呼吸科，北京 100045
- Keywords:
Severe acute respiratory syndrome coronavirus 2 infection;
Immunoprophylaxis;
Severe acute respiratory syndrome coronavirus 2 vaccine;
Maternal vaccinati
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(14):1041-1045
- CountryChina
- Language:Chinese
-
Abstract:
Immunoprophylaxis refers to the strategy to enhance specific immunity of the body through artificial methods, which can be divided into active immunization(mainly vaccination) and passive immunization (including maternal vaccination). Vaccination is the most cost-effective measure to prevent and control the novel coronavirus disease 2019 (COVID-19). Recently, the United States, Costa Rica and Australia have authorized use of the COVID-19 vaccine for children down to 6 months of age.In real-world evaluation, maternal vaccination was associated with a substantial reduction in incidence of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection, the risk of COVID-19 related hospitalization and critical illness among infants younger than 6 months of age.Coupled with these advances in young children, it is possible to achieve the whole population coverage of SARS-CoV-2 immune prevention.
